Molecular Pathology Laboratories

Molecular Diagnostics Laboratories

The Molecular Diagnostics Laboratory (MDL) and Clinical Genomics Laboratory (CGL) in the Division of Genomic and Molecular Pathology are CLIA-certified laboratories employing the latest in next generation sequencing (NGS) and other genomics technologies to provide diagnostics support for University of Chicago patients and others in our network.  Our mission includes a significant focus on cancer, where we aim to best facilitate diagnosis, prognosis, targeted therapy selection and patient monitoring for both solid tumor and hematological malignancy patients.   In addition to a variety of cancer analysis gene sequencing panels, the laboratories collectively perform molecular diagnostics for key markers in leukemias and lymphomas, utilize identity testing to diagnose molar pregnancies and monitor patients following bone marrow transplantation, and perform a variety of tests for markers of disease risk. The test menus are here: Molecular Diagnostics and Next-generation sequencing

IMG_5424.jpg

In the News

Recently, the CGL launched their largest comprehensive NGS cancer profiling panel, UCM-OncoPlus, which involves sequencing 1,212 genes for detection of mutations, indels, copy number changes and select gene fusions, with a currently reportable subset of 119 genes (soon to be expanded) currently reported into the medical record.  Of large scale NGS panels in service within United States academic medical centers for routine patient care, UCM-OncoPlus is perhaps the most comprehensive.  This panel is now a mainstay of cancer care at the University of Chicago, and additionally helps support clinical trial recruitment and translational research projects.

Future Goals

The Molecular Diagnostics Laboratories  are engaged in a number of current development projects to expand our cancer analysis portfolio to include circulating tumor DNA analysis, minimal residual disease detection, and expanded capabilities for detection of other cancer-specific structural variants and epigenetic findings.  We are always happy to engage in collaborations to help develop novel methodologies for genomic analysis to support diagnostics, clinical trials, or translational research.  Please contact us for more information.